2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT

por Helsby, N A, Ferry, D M, Patterson, A V, Pullen, S M, Wilson, W R
Publicado 2004

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line

por Saunders, M P, Patterson, A V, Chinje, E C, Harris, A L, Stratford, I J
Publicado 2000

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

por Chinje, E C, Patterson, A V, Saunders, M P, Lockyer, S D, Harris, A L, Stratford, I J
Publicado 1999

Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.

por Patterson, A. V., Zhang, H., Moghaddam, A., Bicknell, R., Talbot, D. C., Stratford, I. J., Harris, A. L.
Publicado 1995

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

por Patterson, A. V., Barham, H. M., Chinje, E. C., Adams, G. E., Harris, A. L., Stratford, I. J.
Publicado 1995

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

por Patterson, A. V., Saunders, M. P., Chinje, E. C., Talbot, D. C., Harris, A. L., Strafford, I. J.
Publicado 1997

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha

por Braybrooke, J P, Propper, D J, O’Byrne, K J, Koukourakis, M I, Patterson, A V, Houlbrook, S, Love, S D, Varcoe, S, Taylor, M, Ganesan, T S, Talbot, D C, Harris, A L
Publicado 2000